Pre-operative levels of serum vascular endothelial growth factor A (VEGF-A), C (VEGF-C) and D (VEGF-D) in non-small cell lung cancer (NSCLC). Preliminary report
M. Kozlowski, O. Kowalczuk, G. Lapuc, A. Sulewska, W. Laudanski, M. Garbowicz, W. Niklinska, P. Dziegielewski, L. Chyczewski, J. Niklinski, J. Laudanski (Bialystok, Poland)
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Kozlowski, O. Kowalczuk, G. Lapuc, A. Sulewska, W. Laudanski, M. Garbowicz, W. Niklinska, P. Dziegielewski, L. Chyczewski, J. Niklinski, J. Laudanski (Bialystok, Poland). Pre-operative levels of serum vascular endothelial growth factor A (VEGF-A), C (VEGF-C) and D (VEGF-D) in non-small cell lung cancer (NSCLC). Preliminary report. Eur Respir J 2008; 32: Suppl. 52, 1405
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt-1, VEGF-R2-KDR/Flk-1) as prognostic indicators in small cell lung carcinomas (SCLC) Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker? Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007
The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
LATE-BREAKING ABSTRACT: Expression of macrophage migration inhibitory factor (MIF) in the serum and lung tissues in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012
The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004
Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015
Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) as a prognostic factor of survival in patients with lung adenocarcinoma Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018
Targeting gene of insulin-like growth factor type I (IGF-I) on in vitro model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006
Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009
Investigating new prognostic crossroads in lung carcinomas; comparing the prognostic potential of vascular endothelial growth factor (VEGF) and its receptors versus endoglin (CD105) Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer Year: 2009
Vascular endothelial growth factor (VEGF) expression in non small cell lung cancer and its association with histopathologic type, stage, lymphnode involvement, recurrence and distant metastasis Source: Eur Respir J 2003; 22: Suppl. 45, 393s Year: 2003
Vascular endothelial growth factor (VEGF) in serum and exhaled breath condensate (EBC) of subjects with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 205s Year: 2007
The clininical value of vascular endothelial growth factor (VEGF) in the development of lung sarcoidosis. Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes Year: 2018
Vascular endothelial growth factor (VEGF) in serum and exhaled breath condensate (EBC) as a potential biomarker for early detection of non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
The clinical significance of serum VEGF C, VEGF D and sVEGFR2 concentration in lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012